Treatment News

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News


February 28, 2007
Isentress (MK-0518) Results Prove Promising
Long-awaited data from two Phase III studies of Isentress (MK-0518) indicate that the integrase inhibitor offers “potent and superior” antiretroviral activity to those in desperate need of new treatment options. 
Encouraging Data from Two Maraviroc Studies
Early data from two studies of maraviroc, Pfizer's entry inhibitor contender, indicate that the drug is proving useful for treatment-experienced patients with multiple-drug-resistant HIV. 
Shift in Cancer-Related Deaths in HIV
Among those with HIV and on antiretroviral treatment, the risk of dying from a non-AIDS-related cancer is now significantly greater than the risk of dying from an AIDS-related cancer.
February 27, 2007
TH9507 Shows Promise for Lipodystrophy
New data from a Phase III clinical trial of TH9507 suggest that this growth hormone promoter may be associated with moderate decreases in visceral fat with fewer side effects seen in clinical trials involving similar compounds.
February 26, 2007
Fosamax, Calcium, and Vitamin D for Bone Weakness
Fosamax, combined with calcium and vitamin D supplementation, proves safe and useful for advanced osteopenia and osteoporosis in HIV. 
Zetia Lowers 'Bad' LDL Cholesterol
The cholesterol-lowering drug Zetia provides useful in the management of moderately increased "bad" LDL cholesterol levels in HIV. 
More Lipoatrophy with Sustiva vs. Kaletra
Data from a clinical trial, presented this past summer, concluded that Sustiva has a few efficacy advantages over Kaletra.  New data from the study suggests that Kaletra may have an advantage of its own: less lipaotrophy than Sustiva.  
One in 10 Infected with Drug-Resistant HIV
New data from the CDC suggest that approximately one in 10 individuals diagnosed with HIV in recent years was infected with HIV strains resistant to at least one available antiretroviral.  
February 23, 2007
Low Risk of Premature Births with HIV Treatment
A review of 14 pregnancy studies suggests that antiretroviral therapy during pregnancy is associated with a very low risk of premature births.
February 21, 2007
HIV Protein to Fight Cancer
Cancer cells keep growing because they don't react to internal signals urging them to die. Researchers are now using an HIV protein to get a messenger into tumors, forcing them to commit suicide.
February 20, 2007
Are We Spending Too Much on HIV?
Billions of dollars are being spent on the fight against AIDS in developing countries. In a new British Medical Journal commentary, two experts go head to head over whether we are spending too much. 
February 16, 2007
Protein Discovery May Aid Vaccine Development
The discovery of a key portion of an HIV surface protein may have positive implications in the development of an effective HIV vaccine.
February 13, 2007
PN Study Supports Medical Marijuana
A San Francisco study indicates that smoking marijuana is safe and effective for the management of peripheral neuropathy pain, which has advocates stepping up efforts to legalize cannabis for medical purposes.
Metabolic Syndrome No More Common in HIV
A new study suggests that metabolic syndrome in HIV-positive people is no more common than in HIV-negative individuals, suggesting that traditional risk factors are more to blame than antiretroviral-related factors. 
February 07, 2007
GSK Offers $50 Savings Card to Lexiva Users
GlaxoSmithKline announced this week that it has introduced a cash savings program for its protease inhibitor Lexiva (fosamprenavir).  The new "Patient Support Cards" will provide some HIV-positive patients with a "credit" of up to $50 toward their out-of-pocket expenses for Lexiva, every time their prescription for the drug is filled for a total of two years.
February 01, 2007
Asthma Med for IRIS?
Doctors in London have reported encouraging results using a common asthma medication to treat an HIV-positive man with immune reconstitution inflammatory syndrome (IRIS). The case report, published in the January 30 issue of AIDS, suggests that the patient’s rapid recovery upon starting treatment with the leukotriene inhibitor montelukast (Singulair) may also provide important information about the mechanisms responsible for IRIS seen in many HIV-positive people receiving antiretroviral therapy.
Despite Setback, Advocates Push for Continued Microbicide Research
HIV prevention advocates are emphasizing the importance of continued research into new HIV prevention options, despite the recent discontinuation of the Phase III effectiveness trials of the microbicide candidate, cellulose sulfate (CS).
More Treatment News

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ



Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Is youth leadership important in the HIV/AIDS fight?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.